DAX24.304 -0,1%ESt505.430 +0,4%Top 10 Crypto13,88 +2,4%Dow42.763 +1,1%Nas19.530 +1,2%Bitcoin92.091 +0,5%Euro1,1399 ±0,0%Öl66,65 +2,1%Gold3.311 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 RENK RENK73 NVIDIA 918422 HENSOLDT HAG000 Lufthansa 823212 Bayer BAY001 Palantir A2QA4J Siemens Energy ENER6Y BYD A0M4W9 Commerzbank CBK100 Novo Nordisk A3EU6F Infineon 623100 BASF BASF11 BioNTech (ADRs) A2PSR2
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Arbeitsmarkt im Fokus: DAX geht etwas schwächer ins Wochenende -- Wall Street mit Zuwächsen -- Spionage-Vorwürfe & Co. verunsichern Palantir-Anleger -- Broadcom enttäuscht -- Tesla, VW im Fokus
Top News
KI-Revolution an der Börse: Warum KI nicht nur bei NVIDIA eine Rolle spielt KI-Revolution an der Börse: Warum KI nicht nur bei NVIDIA eine Rolle spielt
Das sind die aktuellen Preise von Öl, Erdgas & Co. Das sind die aktuellen Preise von Öl, Erdgas & Co.
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Vanda Pharmaceuticals Aktie

Handeln
Aktien-Sparplan anlegen
3,80 EUR -0,02 EUR -0,52 %
STU
4,61 USD +0,23 USD +5,25 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.226,97 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0JJT3

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS9216591084

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolVNDA

Vanda Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireVanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference
PR NewswireVanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
PR NewswireVanda Pharmaceuticals Announces Presentations at SLEEP 2024
PR NewswireVanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders
PR NewswireVanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
PR NewswireVanda Pharmaceuticals Reports First Quarter 2024 Financial Results
PR NewswireVanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
PR NewswireVanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
PR NewswireVanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
PR NewswireVanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
PR NewswireVanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
PR NewswireVanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
PR NewswireVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
PR NewswireVanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
PR NewswireVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
PR NewswireVanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
PR NewswireVanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
PR NewswireVanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clin...
PR NewswireVanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
PR NewswireVanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry
PR NewswireVanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
PR NewswireVanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis
PR NewswireVanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
PR NewswireVanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences
PR NewswireVanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
PR NewswireVanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023
PR NewswireVanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit
PR NewswireVanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
PR NewswireBlackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
PR NewswireVanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
PR NewswireVanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023
PR NewswireVanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference
PR NewswireVanda Pharmaceuticals Announces Presentations at SLEEP 2023
PR NewswireVanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
PR NewswireVanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness
PR NewswireVanda Pharmaceuticals Announces Presentations at DDW 2023
PR NewswireVanda Pharmaceuticals Reports First Quarter 2023 Financial Results

Vanda Pharmaceuticals News

Vanda Pharmaceuticals News: auf dieser Seite finden Sie alle Vanda Pharmaceuticals News und Nachrichten zur Vanda Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Vanda Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Vanda Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.